drugset / Trial / NCT00619996
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to use Sorafenib plus Docetaxel to evaluate pharmacodynamics (PD) in Patients with prostate cancer.
Timeline
- Start
- 2007-03
- Primary completion
- 2008-01
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |